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Purpose: Mowat–Wilson syndrome (MWS) is a rare intellectual
disability/multiple congenital anomalies syndrome caused by hetero-
zygous mutation of the ZEB2 gene. It is generally underestimated because
its rarity and phenotypic variability sometimes make it difficult to
recognize. Here, we aimed to better delineate the phenotype, natural
history, and genotype–phenotype correlations of MWS.
Methods: In a collaborative study, we analyzed clinical data for 87
patients with molecularly confirmed diagnosis. We described the
prevalence of all clinical aspects, including attainment of neurodevelop-
mental milestones, and compared the data with the various types of
underlying ZEB2 pathogenic variations.
Results: All anthropometric, somatic, and behavioral features
reported here outline a variable but highly consistent phenotype.
By presenting the most comprehensive evaluation of MWS to
date, we define its clinical evolution occurring with age and
derive suggestions for patient management. Furthermore, we
observe that its severity correlates with the kind of ZEB2
variation involved, ranging from ZEB2 locus deletions, asso-
ciated with severe phenotypes, to rare nonmissense intragenic
mutations predicted to preserve some ZEB2 protein function-
ality, accompanying milder clinical presentations.
Conclusion: Knowledge of the phenotypic spectrum of MWS and
its correlation with the genotype will improve its detection rate and the
prediction of its features, thus improving patient care.
Genet Med advance online publication 4 January 2018
Key Words: Hirschsprung; intellectual disability; management;
Mowat–Wilson syndrome; ZEB2
INTRODUCTION
Mowat–Wilson syndrome (MWS) (OMIM # 235730) is
characterized by distinctive facial appearance in association
with variable moderate-to-severe intellectual disability (ID),
epilepsy, Hirschsprung disease (HSCR), and multiple con-
genital anomalies, including genital anomalies (in particular
hypospadias), congenital heart disease, agenesis of the corpus
callosum, and eye defects. MWS is caused by deleterious de
novo heterozygous variations in the ZEB2 gene. The majority
of variants lead to haploinsufficiency through premature stop
codons or large deletions.
MWS was first delineated by Mowat et al.1 as a syndromic
condition characterized by distinctive facial phenotype, ID, and
Hirschsprung disease in four of six reported individuals. The
causative genetic defect was mapped to chromosome 2q21-q23
based on cytogenetic deletions in two patients,1,2 and narrowed
to heterozygous mutations of the ZEB2 gene by subsequent
reports.3,4 In 2002 Zweier et al.5 further delineated the
phenotype of MWS with or without HSCR, invariably
characterized by ZEB2 gene defects, and proposed that
the condition be named Mowat–Wilson syndrome. More than
300 patients have been reported so far6–17 (additional reviewed
articles are listed in Supplementary File S1 online).
We carried out a collaborative international study to further
characterize and delineate the phenotype, natural history, and
genotype–phenotype correlation of MWS.
We analyzed clinical data for 87 patients with a molecularly
confirmed diagnosis of MWS, including 62 previously
reported patients and 25 unpublished cases, and compared
them with patients previously reported by other authors. We
obtained these data through collaborations involving clin-
icians from various countries. Such primary data have never
been collated from a large cohort of affected individuals.
In this article we present a comprehensive study of MWS
features underlining a highly consistent phenotype for the disease,
its genotype–phenotype correlations, and the phenotypic and
clinical evolution taking place with age. The purpose of the article
is to assist clinicians to identify the disease and to provide them
with updated care recommendations for patient management.13
MATERIALS AND METHODS
Individuals affected by MWS and with a ZEB2 variation
confirmed by appropriate methods (Supplementary File S2)
were identified with the help of an international working
group of collaborating clinicians and with the support of the
Italian MWS Association. Through the respective clinicians,
we invited them to fill in a highly detailed questionnaire.
Informed consent for inclusion was obtained for all
individuals involved in the study. Separate written informed
consent was obtained for the publication of photographs.
Approval for this study was granted by the Ethical Committee
of Reggio Emilia.
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Clinical and genetic data were transferred to an electronic
database, and processed using the Statistical Package for the
Social Sciences (SPSS, IBM, Chicago, IL), version 20.0. Group
differences in phenotypes were compared using chi-square
and Fisher’s exact tests. Post hoc analysis was applied with
Bonferroni correction for all multiple comparisons. Po0.05
was considered statistically significant.
RESULTS
A total of 87 patients are reported, ranging in age from 6 months
to 36 years, including individuals not previously reported. The
clinical diagnosis of MWS was confirmed by genetic testing in all
of them. Patients originated from four continents and various
ethnic backgrounds, although the vast majority were from
Europe. The male-to-female ratio was 45:42. The mean age at
the last clinical evaluation was 9 years and 10 months.
The main clinical features are presented in Table 1, in
comparison with the literature. All numbers and percentages
are related to the total number of patients that could be
evaluated for a given feature. Figure 1 shows photographs of
patients at various ages. Comprehensive clinical data are
presented in Figure 2.
Family history
The average age of fathers and mothers at time of delivery was
34 years and 6 months and 31 years and 7 months respectively.
No consanguinity was reported. Regarding two affected sisters
presenting the same ZEB2 variant, germ-line mosaicism was
considered because both parents had normal results on testing
the mutation in blood.18 Germ-line mosaicism had already been
considered in some previous reports.19,20
Birth history
The average gestational age was 39 weeks, with a range
between 33 and 43. Weights at birth were within the normal
range in both males and females. The average weight in males
was 3,408 g, with a range between 2,140 g and 4,680 g; the
average weight in females was 3,110 g, with a range between
1,240 g and 4,100 g (Supplementary Table S1). The birth
weight of all males was between the 2nd and 100th centiles for
gestational age (mean 51st centile); the females’ birth weight
was between the 3rd and 100th centiles (mean 54th centile).
Length at birth was within the normal range for almost all
the patients, both males and females. The average birth length
in males was 49.9 cm, with a range between 45.5 and 54 cm
(range 2nd and 99th centiles, mean 44th). The average birth
length in females was 49.2 cm, with a range between 37 and
56 cm (range o1st and 100th centiles, mean 53rd).
Although the average occipital frontal circumference at
birth was within the normal range in both genders, the
majority of patients had circumferences under the 50th
centile, with mean values of 27th centile for males and 31st for
females. In males, the mean was 33.5 cm, with a range
between 29.2 and 37 cm (o1st and 96th centiles); in females,
the mean was 32.6 cm, with a range between 27 and 35 cm
(o1st and 100th centiles).
Head circumference and growth
Microcephaly, i.e., occipital frontal circumference at least 2 SDs
below the mean, was sometimes observed at birth, but more
frequently tended to develop gradually throughout infancy but
not all children were microcephalic (Figure 3a). Postnatally,
microcephaly was noted in 5 of 14 patients (35.7%, mean
47.7± 2.6 cm) in the age range from 0 to 5 years.
The majority of patients had a height below the 50th centile
(68/80, 85%). Short stature was observed in 7 of 29 patients
(24.13%, height 89.4± 14.9 cm) in the age range from 0 to 6
years, in 8 of 25 patients (32%, height 125± 13.4 cm) in the
age range from 6 to 12 years, and in 16 of 25 patients (64%,
height 150.8+16.8 cm) over 12 years. Adult height in males
Table 1 Main clinical features in the present series and comparison with the literature
Our cohort5,21,28;a Literature1–22;a,b Totalc
Gender (male:female) 45:42 138:119 183:161
Microcephaly 55/81 (67.9%) 189/233 (81.1%) 244/314 (77.7%)
Seizures 73/87 (83.9%) 168/220 (76.3%) 241/307 (78.5%)
Hirschsprung disease 26/85 (30.6%) 122/250 (48.8%) 148/335 (44.2%)
Constipationd 37/85 (43.6%) 53/225 (23.5%) 90/310 (29%)
Congenital heart defects 52/85 (61.2%) 141/247 (57.1%) 193/332 (58.1%)
Pulmonary artery sling 3/81 (3.7%) 6/185 (3.2%) 9/266 (3.4%)
Renal anomalies 22/84 (26.2%) 37/149 (24.8%) 59/233 (25.3%)
Genital anomalies 41/79 (51.9%) 64/165 (38.8%) 105/244 (43%)
Hypospadias 28/45 (62.2%) 43/74 (58.1%) 71/119 (59.7%)
Cryptorchidism 25/45 (55.6%) 26/78 (33.3%) 51/123 (41.5%)
Short stature 31/79 (39.2%) 39/72 (54.2%) 70/151 (46.4%)
Pyloric stenosis 3/83 (3.6%) 11/107 (10.3%) 14/190 (7.4%)
Structural eye anomalies 8/83 (9.6%) 14/138 (10.1%) 22/221 (9.9%)
Cleft palate 0/87 (0.0%) 4/140 (2.9%) 4/225 (1.8%)
aAdditional references in upplementary File S1. bPatients with missense mutations in ZEB2 were not included. cOnly features for which we found precise information in
the cited articles were considered. dWith absent or undetermined Hirschsprung disease.
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varied between 155 and 185 cm (n= 9, mean 165.1 cm) and in
females between 146 and 155 cm (n= 2, mean 150.5 cm).
Most patients were of slender build, with normal body
proportions. Body weight was o50th centile in 63 of 76
patients and o3rd centile in 25 of 76.
Overall, height (length) and weight were globally normal at
birth, but often showed marked delay over time. Occipital
frontal circumference, already under the 50th centile at birth,
tended to fall progressively below normal values (Figure 3a).
Facial phenotype
All patients presented a distinctive facial appearance that
renders the condition recognizable (Figure 1). A detailed list
of the facial features is reported in Figure 2a.
Musculoskeletal anomalies
Musculoskeletal anomalies were frequent and various. A
detailed list of skeletal anomalies reported in our cohort can
be found in Figure 2b.
Neurodevelopment, brain anomalies, and epilepsy
MWS patients have moderate to severe ID. Hypotonia is often
found in the first years of life and was detected in 79.1% of
patients (Figure 2c). Developmental milestones such as sitting
and walking were considerably delayed (Figure 2d): the mean
age of sitting unsupported was 17.39 months, and the mean
age of walking was 3 years and 9 months (range: 16 months to
11 years), although some individuals remain nonambulatory
(33 of 86, 38.3%). A number of patients had a wide-based or
ataxic-like gait, and sometimes held their arms up and flexed
at the elbow, typical of individuals with Angelman syndrome.
All milestones for fine motor skills were delayed. The majority
of the oldest individuals (aged over 20 years) require help
with dressing and other everyday activities. Speech rarely
extends to more than a few words, with onset averaging at 4
years. Many patients have absence of speech (58 of 86
(67.4%), 10 of them still under 4 years of age), but show
receptive language skills and communicate successfully using
alternative methods, such as augmentative and alternative
communication (AAC).
P18, infancy
1
7 8 9 10 11 12
1815 16 1713 14
2320 21 2219 24
282725 26
2 3 4 5 6
P18, infancy P18, infancy P18, 2 yr.
P89, 3 yr. P10, 6 yr.
P54, 9 yr. P80, 10 yr. P31, 11 yr. P8, 12 yr. P18, 12 yr. P31, 12 yr.
P6, 15 yr.P30, 14 yr.P40, 14 yr.P29, 14 yr.P19, 14 yr.P23, 12 yr.
P58, 16 yr. P55, 16 yr. P18, 17 yr. P32, 28 yr.
P5, 7 yr. P18, 8 yr. P27, 8 yr. P1, 8 yr.
P35, 3 yr. P61, 3 yr.
Figure 1 Photographs of patients with Mowat–Wilson syndrome at various ages. The numbered temporal sequence (left to right, top to
bottom) shows how facial phenotype changes from infancy to adulthood. Age for each patient (P#) is given in years.
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Figure 2 Clinical data for the presented patients. (a) Facial features, (b) skeletal features, (c) neurological phenotype, (d) developmental milestones,
(e) congenital heart defects, (f) intestinal tract anomalies, (g) urogenital tract anomalies, (h) eye anomalies, (i) dental anomalies, (j) other features, (k)
behavioral phenotype. *Normal developmental milestones range: sitting without support, 5–7 months; walking without support, 10–14 months; first
words, 10–14 months. ASD, atrial septal defect; CHD, congenital heart disease; PDA, patent ductus arteriosus; SG, secondary generalization, VSD,
ventricular septal defect; VUR, vesicoureteral reflux.
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The neuroradiological phenotype in MWS patients, deli-
neated recently,21 was characterized by anomalies of corpus
callosum (79.6% of cases), hippocampal abnormalities
(77.8%), enlargement of cerebral ventricles (68.5%), and
white matter abnormalities (reduction of thickness 40.7%,
localized signal alterations 22%). We also observed large basal
ganglia and cortical and cerebellar malformations.
It was observed that epilepsy was one of the most frequently
detected features of MWS. Of the 87 patients in our cohort,
83.9% were found to have had seizures (n= 73/87) with a
mean onset occurring at the age of 27.5 months. The most
precocious onset in our cohort was registered at 1 month of
age and the latest onset at 11 years of age. Our studies showed
that 45% of patients have suffered fever-triggered seizures,
72.1% focal seizures, 50.8% generalized seizures, and 40%
focal seizures with secondary generalization. In addition,
25.9% of patients had resistance to antiepileptic drugs
(Figure 2c).
Cardiac anomalies
Congenital heart disease occurred in 60.5% of patients (52/86)
(Figure 2e). The most frequent cardiac anomalies (>25% of
cases) were not complex heart diseases and included patent
ductus arteriosus, ventricular septal defect, and atrial septal
defect. Pulmonary stenosis was present in almost 20% of
patients and aortic coarctation in more than 10%. Other
congenital heart defects with an incidence lower than 10%
included bicuspid aortic valve, aortic valve stenosis, tetralogy
of Fallot, pulmonary artery sling, proximal pulmonary artery
stenosis, mitral valve prolapse, and pulmonary atresia.
Gastrointestinal tract
Constipation and Hirschsprung disease were frequent,
occurring in 43.5% and 30.6% of patients, respectively
(Figure 2f). Less common clinical features were inguinal
hernia and pyloric stenosis.
Urogenital/renal anomalies
Urogenital anomalies were detected in 49 of 80 patients (61.25%;
Figure 2g). The most frequent were hypospadias and crypto-
rchidism. Less common urogenital anomalies were webbed penis,
microphallus, bifid scrotum, and vaginal septum. Renal anomalies
included hydronephrosis, vesicoureteric reflux and, much more
rarely, pelvic kidney.
Eye anomalies
The most frequent anomaly by far was strabismus (56.8%;
Figure 2h). Quite common conditions were astigmatism, more
common in females than in males (F:M= 2.6:1, P= 0.031), and
myopia. Less frequent anomalies were nystagmus, palpebral
ptosis, Axenfeld anomaly, microphthalmia, and irides
heterochromia. Coloboma was present in only one patient.
Tooth anomalies
The two most frequent anomalies reported in our group were
widely spaced teeth (50%) and delayed tooth eruption (47.7%)
(Figure 2i). Other less frequent but still fairly common
anomalies were malpositioned teeth (34.3%) and dental
crowding (26.4%).
Other clinical features
Recurrent otitis media was frequent, detected in 34.6% of
patients. This feature must be taken into account whenever
children present with fever because affected children tend to
have a high pain threshold. It can contribute to conductive
hearing loss, which in our cohort was present in 9 of 77
patients (11.6%). Sensorineural hearing loss was less common
(4/77, 5.2%).
Repeated vomiting attacks were fairly common, with 14 of
77 patients detected (18.2%).
Skin anomalies included hyperpigmentation (12/79, 15.2%),
depigmentation (10/78, 12.8%), and accessory nipples
(8/80, 10%).
Asplenia was fortunately rare (only 1 patient in our cohort),
but it is important to investigate its presence, since it has been
associated with serious infections (Figure 2j).
Behavioral phenotype
Some behavioral types were particularly frequent (present in
over 60% of patients), including chewing or mouthing objects
or body parts, underreaction to pain, and grinding of teeth.
Other patterns, such as laughing for no obvious reason,
fidgeting (flicking, tapping, and twirling of objects), unrealis-
tic happiness or elation, switching lights on and off (more
common in males than in females), rapid mood changes,
standing close to others, and eating nonfood items, were also
common (30–50%; Figure 2k).
Genotype
All the genetic defects in our cohort were heterozygous,
including chromosome deletions encompassing the ZEB2
locus on 2q21-q23 (detected by comparative genomic
hybridization and multiplex ligation-dependent probe ampli-
fication), exon deletions (detected by multiplex ligation-
dependent probe amplification), and several different intra-
genic mutations (detected by direct sequencing).
Chromosome deletions (11.5%) involved an entire ZEB2
allele or its first exons, and ranged in length from a few
hundred kilobases to 16.7 Mb. Additionally, we found two
intragenic deletions: one no larger than 11 kb and comprising
exons 8–9 and the other no larger than 28 kb, encompassing
exons 5–8, and leading to an altered reading frame down-
stream of the deletion.
The majority of pathogenic defects were intragenic muta-
tions, either nonsense mutations (37.9%), or small insertions/
deletions/indels (46%) generating a frameshift and a pre-
mature stop codon (or, in one case, a longer protein with an
altered C-terminus sequence).
Other variants included a deletion in the 3′ UTR region of
ZEB2, probably altering transcript synthesis or regulation, and
an intronic variation altering the splice acceptor site of exon 2,
expected to generate a shorter protein with an altered
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N-terminus sequence by similarity to the variant observed by
Zweier et al.22
No patients with missense mutations were detected.
Genetic defects in our cohort are summarized in
Supplementary Table S2 online and Figure 3b,c.
DISCUSSION
With more than 300 patients reported to date, MWS has
become a well-known entity in clinical dysmorphology.
Distinctive facial appearance is the most reliable clinical
feature for recognizing this condition. Despite the fact that the
facial gestalt is consistent with this diagnosis from an early
age, a change in certain facial features with age has been
reported.15 In childhood, earlobes seem to be uplifted, with a
central depression, and eyebrows are large, medially flaring,
and sparse in the middle. Facial features at this age also
consist of a rounded skull, sparse and fine hair, puffy anterior
neck, and excess skin on the rear of the neck. In childhood,
the face is square with a high forehead, frontal bossing,
epicanthal folds, hypertelorism, telecanthus, large and deep-
set eyes, strabismus, a broad nasal bridge, a rounded nasal tip,
a prominent columella, an open mouth with an M-shaped
upper lip, and a prominent and triangular chin. In addition,
children with MWS tend to smile frequently. In children of
school age, the face is longer, with a prominent jaw. The
eyebrows are broad, usually exhibiting sparseness in the
middle part.
Beginning in adolescence, the eyebrows often become
heavier, broad, and horizontal; the nasal profile is more
convex; the nasal tip lengthens, becomes more depressed, and
overhangs the philtrum; the face tends to lengthen; and a
long, pointed, or “chisel-shaped” chin may be observed.
The uplifted earlobes do not alter significantly over time
apart from the central depression, which is less noticeable in
adults, and this feature is useful in confirming suspicion of
this condition.
What is most useful for clinicians to identify this condition
is the overall facial gestalt, which changes over time. Figure 2a
lists the most frequent facial features in our cohort in order of
frequency. Two patients presented 25 of 26 facial features; the
average number was 15.8. The three most frequent features
(uplifted earlobes, a rounded nasal tip, and a prominent
columella) were present together in 40 patients.
Before the delineation of a facial phenotype, HSCR was
considered the hallmark of MWS. This led to reports of a high
proportion of MWS patients with HSCR and underdiagnosis
of patients with MWS but without HSCR. Afterward, as more
MWS patients without HSCR were identified based on other
features, the frequency of HSCR began to decrease. After
reviewing the literature and analyzing our cohort’s results, we
concluded that the combined frequencies of HSCR and
constipation were above 72%. The difference in HSCR
frequency in our cohort and the literature (30.6% vs. 48.8%)
reflects an enhanced knowledge of the clinical phenotype,
which leads to the fact that patients are now not diagnosed on
the basis of the presence of HSCR but rather on the basis of
the facial gestalt. Because a considerable number of cases with
severe constipation were not investigated by rectal biopsy due
to risk of complications or lack of compliance, it is possible
that the presence of HSCR is now underestimated. The data
regarding the length of the aganglionic segment is not
exhaustive in previously published cases, including our
cohort. However, short and long segments have been reported
both in males, in whom HSCR was more frequent, and in
females.
Of note, although pulmonary artery sling with or without
tracheal stenosis is quite rare (3.7%), in the general population
this cardiac anomaly is present in 1 of 17,000 school-aged
children (0.006%).23 This would make pulmonary artery sling
more common in MWS patients, and we can therefore
consider it a sign that may lead us to suspect MWS.
Ophthalmological findings have already been associated
with MWS.24 Strabismus is the most common finding,
followed by astigmatism, with a 2.6 times higher frequency
in girls. Structural anomalies are rare, with Axenfeld anomaly
and coloboma the most frequent.
Behavioral phenotypes in MWS have been delineated
previously.25 According to our observations of the affected
individuals, one feature requires special attention. Over 60%
of patients (42 of 65) show underreaction to pain, which can
be dangerous for these children. A recent study showed that
the underreaction to pain results from a reduced responsivity
to nociceptive stimulation rather than an inability to
communicate discomfort.26
One of the major challenges posed by MWS is the
recurrence of seizures.27 In 2013 Cordelli et al.28 hypothesized
that a distinct electroclinical phenotype featuring focal and
atypical absence seizures (which are often preceded by febrile
seizures) and age-dependent electroencephalogram changes
can be detected in the majority of patients with MWS.
Moreover, a recent paper21 provided no evidence of a
significant correlation between the brain malformation
phenotype and the epilepsy phenotype in our cohort. This
reinforces the hypothesis put forward by Cordelli et al.29 that
epilepsy in MWS has a genetic etiology.
The prevalence of MWS is low, which makes it still
unknown to the majority of clinicians. This means that
clinicians (pediatricians, neurologists, and/or clinical geneti-
cists and genetic counselors) should be responsible for the
coordination of patients’ care and management. As the
number of adult patients is increasing, the role of neurologists
and clinical geneticists tends to become even more important.
Multidisciplinary follow-up is essential and should consist of
regular evaluations performed by different specialists; in the
first place, pediatricians, neurologists, cardiologists, nephrol-
ogists, and gastroenterologists, especially during early child-
hood. Because there is no cure at this time, the goal of follow-
up is improving quality of life. We strongly recommend AAC
as a key point for MWS patient care. AAC has been
recognized as a valuable tool to stimulate patients’ commu-
nication skills, thus facilitating clinicians and parents in their
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compliance and determination of the behavioral phenotype. A
detailed follow-up summary is reported in Table 2.
Genotype–phenotype correlation
We have grouped the genomic defects involving a single allele
of ZEB2 into three major categories: deletions encompassing
the whole gene, intragenic variants resulting in no protein
synthesis/fast protein degradation, and intragenic variants
resulting in synthesis of a defective protein.
The relatively small number of cases and the scarcity of
functional data make it difficult to establish genotype–
phenotype correlations and assess their statistical significance,
particularly where intragenic mutations are concerned.
Only a few clinical features show some level of significance
for genotype–phenotype correlation (Supplementary Table
S3), and they consistently involve comparing full-gene
deletion with another genotypic category. These locus
deletions often span several megabases of DNA and include
other genes and long noncoding RNAs, such as the ZEB2-
antisense transcripts encoded in the 5′ portion of ZEB2 and
involved in its transcriptional regulation.30 The variability and
extent of these deletions may explain why they are usually
associated with increased severity of some aspects, such as
sitting age and onset of speech (Figure 3d). Full-gene
deletion, or to a lesser extent the presence of a residual
defective protein, also seems to negatively influence the
number of cardiac defects, although their combined numbers
are too small compared with cases of protein absence due to
intragenic mutations (Figure 3e).
Transcripts from ZEB2 alleles with intragenic mutations are
mostly predicted to undergo nonsense-mediated messenger
RNA decay, or to generate very short and allegedly
Table 2 Summary of clinical follow-up and issues to be considered in an emergency situation
Clinical evaluation/instrumental test Frequency
Pediatric assessment with measuring of growth parameters At time of diagnosis, every 6 months in the first 3 years of life, then yearly.
Neurological evaluation (including electroencephalogram when awake and
when asleep, brain magnetic resonance image, and polysomnography) and
psychological treatment
At time of diagnosis, in cases of suspect symptoms for epileptic fits and then
according to the evolution. Rehabilitation therapy is required and should be
started as soon as possible. AAC is recommended.
Cardiological evaluation (including electrocardiogram and echocardiogram) At time of diagnosis and then at intervals determined by the congenital
anomalies that may be present.
Pediatric gastroenterological evaluation In case of suspect HSCR in the first months of life and then at intervals
determined by the clinical problems that may arise.
Abdominal ultrasound (especially for presence/absence of spleen) At time of diagnosis and then yearly or at intervals determined by clinical
problems.
Ocular assessment At time of diagnosis then semiannually until the age of 6 or according to
clinical problems.
Hearing evaluation At time of diagnosis and then at intervals determined by clinical problems.
Dental assessment Yearly from the age of 3.
Orthopedic/physical medicine assessment At time of diagnosis and then at intervals determined by clinical problems.
Surgical evaluation at infant age Based on clinical evidence.
Dietary assessment Based on clinical evidence.
Immunological pediatric evaluation In children with asplenia.
Spine X-rays Based on clinical evidence.
Hematological tests: routine blood chemistry (blood count, renal and liver
function, glucose), APTT, PT-INR, immunological tests (IgG, IgA, IgM, and
lymphocyte subpopulations),a thyroid function tests (thyroxine FT4, TSH
levels), thyroid autoantibodies (TPOAb, TGAb), antitransglutaminase
antibodies, IGF1, IGFBP3
At time of diagnosis, then yearly.
Acute complication Age range
Repeated epileptic seizures Especially in early childhood.
Aspiration pneumonia All ages.
Heart failure in patients with congenital heart disease Especially in neonatal and early childhood.
Gastrointestinal anomalies and complications of Hirschsprung disease (intestinal occlusion, enterocolitis) Especially in neonatal and early childhood.
Serious infections, sepsis In children with asplenia.
Hematemesis/melena for bleeding from gastroesophageal reflux esophagitis All ages.
Acute otitis All ages.
AAC, augmentative and alternative communication; APTT, activated partial thromboplastin time; HSCR, Hirschsprung disease; PT/INR, prothrombin time/international nor-
malized ratio; TSH, thyroid-stimulating hormone.
aAlso IgG subclass in children with asplenia.
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nonfunctional peptides. Here the variability of clinical
presentations is likely due to a series of environmental and
possibly genetic or epigenetic cofactors. Missense mutations
of ZEB2 are a rare occurrence and were found in none of our
cases. They have been described in the literature in association
with mild presentations sharing some similarity with
MWS,31,32 although it is debatable whether most of these
atypical cases should actually be classified as MWS.
However, in addition to patients with missense mutations,
there are a few cases also expected to behave differently than
typical haploinsufficiency. Notably, the least severely affected of
our patients (P23)—a 12-year-old girl with typical facial features
but mild to moderate ID, no seizures, absence of HSCR—has a
frameshift mutation predicted to disrupt only part of the
C-terminal zinc-finger domain: c.3031delA, p.(S1011Afs*64).
Our preliminary studies, involving ZEB2 recombinant con-
structs expressed in a HEK293T cell line, indicate that this
variant protein correctly localizes in the nucleus and retains
some repressor ability on the E-cadherin promoter in a dual
luciferase assay (unpublished data), possibly explaining the
favorable clinical phenotype. Another patient (P34) with a very
mild clinical presentation has a splicing defect that alters only
the N-terminal portion of the protein and abolishes the NuRD
interacting motif, similarly to what was found in another
patient.22 These observations seem to indicate that whenever a
variant ZEB2 protein is predicted to preserve some of its
functionality, we can expect a milder clinical presentation. The
reverse might not always be the case, however; some mild cases
have been found to have mutations abolishing ZEB2 protein
function, suggesting the contribution of other genetic or
environmental factors in shaping the MWS phenotype.
Conclusions
This paper analyzes data from the largest group of MWS
patients reported to date.
Despite the variability of many features, MWS has a
distinctive phenotype and is also genetically homogeneous, as
all patients have a de novo mutation in a single gene, ZEB2,
except for the rarest of cases in which a germ-line mosaicism
has been proved in one of the parents.
The facial gestalt is easily recognizable, apart from the very
rare patients with missense mutations. These should be discussed
case by case as to whether a patient actually has MWS.
Since short stature is one of the most common features, we
are currently collecting additional data to generate specific
growth charts that will aid clinicians to improve the
management and follow-up of children with MWS.
With the growing use of whole-exome sequencing for genes
causing ID, we will undoubtedly identify ZEB2 mutations in
patients who have a less obvious diagnosis of MWS. The study of
these patients, as well as those with a milder phenotype and those
with missense mutations, can help to define the boundaries of this
condition. Better knowledge of the phenotypic spectrum of MWS
and its genotype–phenotype correlations is likely to improve the
detection rate of this condition and facilitate prediction of some
MWS characteristics and a correct approach to some important
features, such as epileptic seizures. This will hopefully aid in
improving care for the patients and bringing much-needed
support to their families.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the
paper at http://www.nature.com/gim
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